Stocks
Heron Therapeutics (HRTX) EBITDA margin US GAAP (year values) |
|||||||||
| FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | LTM ? | 5 years average | |||
| EBITDA margin, % | ? | -249.3% | -164.1% | -81.7% | -3.50% | -11.5% | -13.6% | ||
| Changes by years, y/y, % | +2pp | +85pp | +82pp | +78pp | -8pp | -102% | |||
Heron Therapeutics. EBITDA margin, %
Heron Therapeutics. EBITDA margin, changes, pp
Heron Therapeutics (HRTX) EBITDA margin US GAAP (quarter values) |
||||||||
| FY2025Q2 | FY2025Q3 | FY2025Q4 | FY2026Q1 | FY2026Q2 | LTM ? | |||
| EBITDA margin, % | ? | -4.76% | -36.6% | -3.49% | -21.8% | -13.4% | -13.6% | |
| Changes by years, y/y, % | +11pp | -25pp | -25pp | -31pp | -9pp | |||
| Changes by quarters, q/q, % | -14pp | -32pp | +33pp | -18pp | +8pp | |||
